David M. Reed

David M. Reed

Auto-generated profile, based on publicly available information

David M. Reed

Department of Ophthalmology and Visual Sciences, The Ohio State University, Columbus, Ohio, United States

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2011 in Archives of Ophthalmology (1950)
Verified
Journal Article
Open access
PDF file
JSJoshua D. Stein
Joshua D. Stein
LPLouis R. Pasquale
Louis R. Pasquale
NTNidhi Talwar
Nidhi Talwar
DKDenise S. Kim
Denise S. Kim
DRDavid M. Reed
David M. Reed
JRJulia E. Richards
Julia E. Richards
Exfoliation syndrome (ES) is an extracellular deposit disorder that causes significant ocular morbidity. Quiz Ref ID It is the most common cause of secondary open-angle glaucoma.1 Elevated intraocular pressure commonly results because exfoliation material and uveal pigment lodge in the ocular outflow pathway, although glaucoma associated with ES is clearly multifactorial.2 In addition, ES is cataractogenic,3 and cataract surgery in affected eyes can be fraught with complications,4 due largely to inherent zonular instability.5,6 In ES, gray-white deposits are readily visible in the ocular anterior segment using minimal magnification. These aggregates consist of macromolecules mostly involved in basement membrane biosynthesis,7-11 although markers of complement activation, oxidative stress, ischemia, and inflammation are also found.12 In contrast to the ocular deposits in ES, electron microscopy is typically needed to demonstrate exfoliation material in visceral organs,13,14 which are more insulated from environmental effects, such as ambient temperature, compared with the eye.15 Furthermore, although ES has nonophthalmic manifestations, such as hyperhomocystemia16-21 and sensorineural hearing loss,22-27 the evidence for other prominent systemic features is not entirely clear.28

4 September 2013 in Human Genetics
Verified
Journal Article
Closed access
PDF file
NCNEIGHBOR Consortium
NEIGHBOR Consortium
AOA. Bilge Ozel
A. Bilge Ozel
SMSayoko E. Moroi
Sayoko E. Moroi
DRDavid M. Reed
David M. Reed
MNMelisa Nika
Melisa Nika
JLJun Z. Li
Jun Z. Li

27 February 2006
Verified
Journal Article
Closed access
FRFrank W Rozsa
Frank W Rozsa
DRDavid M Reed
David M Reed
KSKathleen M Scott
Kathleen M Scott
HPHemant Pawar
Hemant Pawar
SMSayoko E Moroi
Sayoko E Moroi
JRJulia E Richards
Julia E Richards

1 May 2005 in Archives of Ophthalmology (1950)
Verified
Journal Article
Closed access
PDF file
RBRodney S. Bucher
Rodney S. Bucher
EHEdward Hall
Edward Hall
DRDavid M. Reed
David M. Reed
JRJulia E. Richards
Julia E. Richards
MJMark W. Johnson
Mark W. Johnson
DZDavid N Zacks
David N Zacks
Research from JAMA Ophthalmology — Effect of Intravitreal Triamcinolone Acetonide on Susceptibility to Experimental Bacterial Endophthalmitis and Subsequent Response to Treatment

1 May 2019 in Current Opinion in Ophthalmology
Verified
Journal Article
Closed access
SMSayoko E. Moroi
Sayoko E. Moroi
DRDavid M. Reed
David M. Reed
DSDavid S. Sanders
David S. Sanders
AAAhmed Almazroa
Ahmed Almazroa
LKLawrence Kagemann
Lawrence Kagemann
JRJulia E. Richards
Julia E. Richards
Approximately 10% of patients become blind despite using evidence-based guidelines developed from clinical trials and epidemiology studies. Our purpose is to review opportunities to decrease glaucoma-related blindness using the emerging principles of precision medicine. The current review focuses on three topics: first, candidate biomarkers for angle-based surgeries, second, head-mounted display (HMD) technology for vision and testing, and third, glaucoma risk alleles discovered by genome-wide association studies. First, in angle-based surgeries, tracers injected into the anterior chamber or Schlemm's canal have allowed visualization of aqueous veins. We describe an innovative use of optical coherence tomography angiography to visualize aqueous veins in a case with 6-year successful outcome following catheter-based trabeculotomy. Second, HMD technology can augment perceived vision and can be used for perimetry testing. Third, developing genetic risk scores that characterize patients who are at highest risk for blindness is a priority. Such biomarker risk scores will integrate genome-wide association study-based risk alleles for glaucoma along with well known demographic and clinical risk factors. As we gain more knowledge, precision medicine will enable clinicians to decrease glaucoma-related blindness by providing more timely interventions to those patients who are at highest risk for progression to blindness. http://links.lww.com/COOP/A29.

21 September 2004 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
SSSatoko Shimizu
Satoko Shimizu
CKCharles Krafchak
Charles Krafchak
NFNobuo Fuse
Nobuo Fuse
MEMichael P. Epstein
Michael P. Epstein
MSMiriam T. Schteingart
Miriam T. Schteingart
JRJulia E. Richards
Julia E. Richards